Systemic therapy for biliary cancers

Area of Science:

• Oncology
• Gastroenterology
• Genetics

Background:

• Biliary tract cancers (gallbladder cancer and cholangiocarcinoma) are uncommon, heterogeneous malignancies often diagnosed at advanced stages.
• Current standard first-line treatment is cisplatin plus gemcitabine, but outcomes remain disappointing, necessitating improved therapeutic strategies.

Purpose of the Study:

• To review first-line systemic chemotherapy regimens, targeted therapies (EGFR, VEGF), and the role of second-line chemotherapy for biliary tract cancers.
• To highlight the molecular diversity of biliary cancers and the evolving role of targeted therapy and immunotherapy.
• To emphasize the need for biomarker-driven clinical trials for improved patient outcomes.

Main Methods:

• Overview of prior first-line studies including single, doublet, and triplet chemotherapy regimens.
• Review of targeted therapy combinations (EGFR, VEGF) and current second-line chemotherapy approaches.
• Discussion of molecular profiling, targeted therapies (FGFR2, IDH1/2), and immunotherapy in biliary cancers.

Main Results:

• Combination chemotherapy is superior to single-agent therapy in the first-line setting for biliary tract cancers.
• No established standard of care exists for second-line therapy; clinical trial enrollment is paramount.
• Molecular profiling identifies actionable targets, such as FGFR2 fusions and IDH1/2 mutations, particularly in intrahepatic cholangiocarcinoma.

Conclusions:

• Despite advances, outcomes for biliary tract cancers remain challenging, underscoring the need for novel treatment strategies.
• Future clinical trials must incorporate biomarkers for prognosis and treatment prediction.
• Targeted therapies and immunotherapy hold significant promise for improving outcomes in biliary tract cancers.